Merck & Co has agreed to buy Afferent Pharmaceuticals, and its lead respiratory drug, in a deal worth up to $1.25 billion. The acquisition comes at a time when Merck’s revenues are beginning to ...

Afferent Also Appoints Kathleen Sereda Glaub to the Company's Board of Directors SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals today announced that Michael M. Kitt, M.D., has been named ...

The autonomic nervous system innervates all body organs, including the cardiovascular system. Smooth muscle in arteries, arterioles, and veins and pericytes in capillaries receive autonomic ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds targeting P2X3 for the treatment of respiratory and urologic disorders, as well as ...

New company raised $23 million in a Series A financing round. A new company Afferent Pharmaceuticals has been founded with $23 million in Series A funding to develop new treatments for chronic pain ...

Merck & Co’s purchase of Afferent Pharma last year was all about a candidate drug for chronic cough – so it will be celebrating now the drug has just shown promise in a phase II trial. Merck (known as ...

KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have ...

- Neuroscience Industry Veteran to Lead Development of Chronic Pain Treatments; Technology Targets Novel Biological Pathway - PALO ALTO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a ...

Merck & Co. (MRK) might be slipping in Friday’s session, but the company is definitely making waves in its industry with its most recent acquisition agreement. Merck and Afferent Pharmaceuticals ...